目的：观察比较玻璃体腔注射康柏西普与阿柏西普治疗厚脉络膜新生血管病变(PNV)的临床疗效及安全性。

方法：回顾性病例对照研究。收集2018-02/2022-10于我院确诊为PNV的患者33例35眼，根据玻璃体腔注射药物分为康柏西普组14例14眼，阿柏西普组19例21眼，比较两组患者治疗前，治疗后1、3、6mo的最佳矫正视力(BCVA)、黄斑中心凹下脉络膜厚度(SFCT)、黄斑中心凹视网膜厚度(CMT)、注药次数及临床并发症的情况。

结果：治疗后1、3、6mo，两组患者的BCVA、CMT、SFCT较治疗前均明显改善(均P<0.05)； 在整个随访期间，两组患者玻璃体腔注射次数分别为2(2，3)、2(1.5，2)次，未见明显差异(P=0.423)； 在应用康柏西普及阿柏西普的治疗过程中，均未发生严重的并发症。

结论：玻璃体腔注射康柏西普及阿柏西普均能治疗PNV，在提高视力的同时改善解剖结构，两种药物疗效相似，均能达到较为理想的临床效果。

METHODS:Retrospective case-control study. A total of 33 patients(35 eyes)diagnosed as PNV in our hospital from February 2018 to October 2022 were divided into 14 cases(14 eyes)in conbercept group and 19 cases(21 eyes)in aflibercept group according to the treatment methods. The best corrected visual acuity(BCVA), subfoveal choroidal thickness(SFCT)and central macular thickness(CMT), injection times and clinical complications of the two groups were compared before and 1, 3 and 6mo after treatment.

RESULTS:BCVA, CMT and SFCT in both groups were significantly improved after 1, 3 and 6mo of treatment(all P<0.05). During the whole follow-up period, the number of intravitreal injections in the two groups were 2(2, 3)and 2(1.5, 2)respectively, and there was no significant difference(P=0.423). No serious complications occurred during the treatment of the two groups.

CONCLUSION:Both intravitreal injections of conbercept and aflibercept can treat PNV with similar therapeutic effects. The desired clinical outcome is achieved by improving the anatomy while improving visual acuity.